X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CB03 as a KCNQ2/3 potassium ion channel opener thus has its potential for become a safe and effective treatment option for ALS and other CNS diseases.
Lead Product(s): CB03
Therapeutic Area: Neurology Product Name: CB03
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
ZM-H1505R is a small-molecule HBV capsid assembly modulator with a novel pyrazole structure currently being evaluated for the treatment of CHB. It is active against most HBV variants that show resistance to other HBV capsid modulators.
Lead Product(s): ZM-H1505R
Therapeutic Area: Infections and Infectious Diseases Product Name: ZM-H1505R
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
CB03 is a new generation of KCNQ2/3 potassium channel opener, has a more specific ion channel selectivity and is unlikely to present the same safety concerns as retigabine.
Lead Product(s): CB03
Therapeutic Area: Neurology Product Name: CB03
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
CB06 is a small molecule, oral TLR8 agonist independently developed by Zhimeng, and it is the second candidate with exclusive intellectual property that successfully enters the clinical development stage, within Zhimeng’s innovative pipelines.
Lead Product(s): CB06
Therapeutic Area: Infections and Infectious Diseases Product Name: CB06
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2022
Details:
Primary results showed that the drug is safe and well tolerated in health volunteers tested.
Lead Product(s): ZM-H1505R
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
